Real-World Effectiveness of MIGSPRAY: A Dual-Action Nasal Spray for Migraine Prevention Through Mechanical Barrier and Osmotic Sinus Decongestion

Background: Migraine is a common neurological disorder affecting over 10% of the global population and is a leading cause of disability. Various triggers, including environmental and chemical irritants, are known to activate the trigeminal system, contributing to the onset of migraines. MIGSPRAY, a nasal spray composed of natural filmogen glycerol and plant-based polymers, has been developed as a novel treatment to prevent migraines. Its dual mechanism of action includes forming a protective barrier on the nasal mucosa to block triggers and exerting strong osmotic properties to naturally decongest the sinuses.Objective: To evaluate the effectiveness of MIGSPRAY in reducing the frequency, intensity, and duration of migraines in a real-world population, and to confirm the findings from a previous randomized clinical trial.Methods: This observational study followed 322 patients with a history of migraines over a 3-month period. Eligible patients were between 12 and 55 years old and experienced at least five migraine days per month. MIGSPRAY was administered twice daily. The primary outcome was the change in the number of migraine days per month. Secondary outcomes included changes in migraine intensity, duration, and disability scores as measured by HIT-6 and MIDAS.Results: After three months of treatment, patients experienced a significant reduction in migraine days (-1.9 ± 0.2 days; 26% reduction, p<0.001), as well as decreases in migraine intensity (-1.1 ± 0.2 on the VAS, p<0.001) and duration (-1.1 ± 0.1 hours, p<0.001). Significant improvements were also observed in HIT-6 and MIDAS scores (p<0.001), indicating reduced migraine-related disability. These results confirm the findings of a previous randomized clinical trial, demonstrating the consistent efficacy of MIGSPRAY in both controlled and real-world settings.Conclusion: MIGSPRAY is a safe and effective non-pharmacological treatment for preventing migraines. By combining mechanical barrier protection and osmotic sinus decongestion, MIGSPRAY significantly reduces migraine frequency, intensity, and disability. The findings from this real-world study confirm the results of prior clinical trials, suggesting MIGSPRAY as a valuable option for migraine management.